Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Retained Earnings (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Retained Earnings for 7 consecutive years, with -$1.1 billion as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 41.26% to -$1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.1 billion through Dec 2025, down 41.26% year-over-year, with the annual reading at -$1.1 billion for FY2025, 41.26% down from the prior year.
  • Retained Earnings for Q4 2025 was -$1.1 billion at Kymera Therapeutics, down from $1.5 million in the prior quarter.
  • The five-year high for Retained Earnings was $1.9 million in Q3 2024, with the low at -$1.1 billion in Q4 2025.
  • Average Retained Earnings over 5 years is -$245.0 million, with a median of -$5.4 million recorded in 2022.
  • Peak annual rise in Retained Earnings hit 178.82% in 2024, while the deepest fall reached 136604.71% in 2024.
  • Over 5 years, Retained Earnings stood at -$660000.0 in 2021, then crashed by 649.85% to -$4.9 million in 2022, then skyrocketed by 88.85% to -$552000.0 in 2023, then tumbled by 136604.71% to -$754.6 million in 2024, then crashed by 41.26% to -$1.1 billion in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$1.1 billion, $1.5 million, and -$896.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.